UCB (OTCMKTS:UCBJY) Lowered to Hold Rating by Zacks Research

Zacks Research lowered shares of UCB (OTCMKTS:UCBJY) from a strong-buy rating to a hold rating in a report issued on Wednesday morning,Zacks reports.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group upgraded UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, UCB presently has an average rating of “Moderate Buy”.

UCB Stock Up 1.4%

Shares of OTCMKTS:UCBJY opened at $119.73 on Wednesday. UCB has a 12-month low of $114.53 and a 12-month high of $168.76. The business has a 50-day moving average price of $128.90 and a 200 day moving average price of $140.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.